(Carboxymethyl-isobutyl-amino)-acetic acid | 60435-60-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (Carboxymethyl-isobutyl-amino)-acetic acid
• 英文别名: 2-[Carboxymethyl(2-methylpropyl)amino]acetic acid
• CAS: 60435-60-1
• 化学式: C₈H₁₅NO₄
• 分子量: 189.211
• InChiKey: YMIIFCSWKDKVSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  异丁胺 、 氯乙酸 生成 (Carboxymethyl-isobutyl-amino)-acetic acid
  参考文献：
  名称：

  Mighri,Z.; Rumpf,P., Bulletin de la Societe Chimique de France, 1975, p. 689 - 694

  摘要：

  DOI：

文献信息

• Molecular Aggregate Capable of Undergoing Phase Transition by Dehydrating Condensation and Method of Phase Transition Thereof
  申请人：Kunishima Munetaka

  公开号：US20090023003A1

  公开（公告）日：2009-01-22

  Provided is a bilayer membrane vesicle capable of undergoing a phase transition. The bilayer membrane vesicle includes: (a) a fatty acid salt having 6 to 20 carbon atoms; (b) an alcohol or an amine compound having an aliphatic chain of 6 to 20 carbon atoms; and (c) an artificial synthetic lipid or a phospholipid capable of forming a bilayer membrane. Preferably, this bilayer membrane vesicle further contains (d) a tertiary amine as a component of the membrane. Also provided is a method of inducing a phase transition of a bilayer membrane vesicle, the method including the step of adding a dehydrating condensing agent or a dehydrating condensing agent precursor having the property of accumulating at an interface to the bilayer membrane vesicle. By causing the lipids that form a molecular aggregate to chemically change, it is possible to change the physical property and the morphology of the molecular aggregate and control the timing of phase transitions such as membrane fusion. In the membrane fusion, for example, fusion can occur without leakage of the contents of the bilayer membrane vesicle.

  提供的是一种能够经历相变的双层膜囊泡。该双层膜囊泡包括：(a)一种含有6到20个碳原子的脂肪酸盐；(b)一种具有6到20个碳原子的脂肪链的醇或胺化合物；以及(c)一种能够形成双层膜的人工合成脂质或磷脂。最好的情况下，这种双层膜囊泡还包含(d)作为膜组分的三级胺。还提供了一种诱导双层膜囊泡相变的方法，该方法包括向双层膜囊泡中加入具有在界面处积聚性质的脱水缩合剂或脱水缩合剂前体的步骤。通过使形成分子聚集体的脂质发生化学变化，可以改变分子聚集体的物理性质和形态，并控制膜融合等相变的时机。在膜融合中，例如，可以在不泄漏双层膜囊泡内容物的情况下进行融合。
• Method of Inducing a Phase Transition of a Bilayer Membrane Vesicle
  申请人：JAPAN SCIENCE AND TECHNOLOGY AGENCY

  公开号：US20130251788A1

  公开（公告）日：2013-09-26

  Provided is a bilayer membrane vesicle capable of undergoing a phase transition. The bilayer membrane vesicle includes: (a) a fatty acid salt having 6 to 20 carbon atoms; (b) an alcohol or an amine compound having an aliphatic chain of 6 to 20 carbon atoms; and (c) an artificial synthetic lipid or a phospholipid capable of forming a bilayer membrane. Preferably, this bilayer membrane vesicle further contains (d) a tertiary amine as a component of the membrane. Also provided is a method of inducing a phase transition of a bilayer membrane vesicle, the method including the step of adding a dehydrating condensing agent or a dehydrating condensing agent precursor having the property of accumulating at an interface to the bilayer membrane vesicle. By causing the lipids that form a molecular aggregate to chemically change, it is possible to change the physical property and the morphology of the molecular aggregate and control the timing of phase transitions such as membrane fusion. In the membrane fusion, for example, fusion can occur without leakage of the contents of the bilayer membrane vesicle.

  提供的是一种能够经历相变的双层膜小泡。该双层膜小泡包括：(a) 6至20个碳原子的脂肪酸盐；(b) 具有6至20个碳原子的脂肪链的醇或胺化合物；以及(c) 能够形成双层膜的人工合成脂质或磷脂。最好，该双层膜小泡还包含(d) 作为膜组分的三级胺。还提供了一种诱导双层膜小泡相变的方法，该方法包括向双层膜小泡添加具有在界面处积累性质的脱水缩合剂或脱水缩合剂前体的步骤。通过使形成分子聚集体的脂质发生化学变化，可以改变分子聚集体的物理性质和形态，并控制膜融合等相变的时间。例如，在膜融合中，可以在不泄漏双层膜小泡内容物的情况下发生融合。
• Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography
  申请人：Wake Forest University

  公开号：US10758634B2

  公开（公告）日：2020-09-01

  Disclosed are novel compounds, complexes, compositions and methods using Zirconium-89 combined with azamacrocyclic chelators in connection with PET. The compositions and methods should provide better diagnostic, prognostic and therapeutic oncology treatments relative to the presently available chelator compositions due to a variety of superior properties of the disclosed compositions. The present invention also relates to a superior method of making these compounds, complexes, compositions that allows one to make compounds/complexes (and thus, compositions) that were previously unattainable.

  所公开的是将锆-89 与氮杂环螯合剂结合用于 PET 的新型化合物、复合物、组合物和方法。与目前可用的螯合剂组合物相比，本发明的组合物和方法应能提供更好的肿瘤诊断、预后和治疗效果，因为本发明所公开的组合物具有多种优异特性。本发明还涉及一种制造这些化合物、复合物、组合物的优越方法，该方法可使人们制造出以前无法制造的化合物/复合物（以及组合物）。
• COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS USING ZIRCONIUM-89 IN IMMUNO-POSITRON EMISSION TOMOGRAPHY
  申请人：Wake Forest University

  公开号：US20190038785A1

  公开（公告）日：2019-02-07

  Disclosed are novel compounds, complexes, compositions and methods using Zirconium-89 combined with azamacrocyclic chelators in connection with PET. The compositions and methods should provide better diagnostic, prognostic and therapeutic oncology treatments relative to the presently available chelator compositions due to a variety of superior properties of the disclosed compositions. The present invention also relates to a superior method of making these compounds, complexes, compositions that allows one to make compounds/complexes (and thus, compositions) that were previously unattainable.
• US8449979B2
  申请人：——

  公开号：US8449979B2

  公开（公告）日：2013-05-28